



do more  
feel better  
live longer

GLAXOSMITHKLINE CONSUMER NIGERIA PLC

UNAUDITED CONSOLIDATED AND SEPARATE FINANCIAL STATEMENTS  
FOR THE PERIOD ENDED 30TH SEPTEMBER 2021

GlaxoSmithKline Consumer Nigeria Plc

Unaudited Consolidated and Separate Statement of Profit or Loss and other Comprehensive Income  
For the period ended 30 September 2021

	<b>GROUP</b>			
	<b>July - Sep 2021</b>	<b>Jan - Sep 2021</b>	<b>July - Sep 2020</b>	<b>Jan - Sep 2020</b>
	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>
Revenue	6,590,171	16,452,582	6,015,682	16,447,206
Cost of sales	(4,996,727)	(12,084,198)	(4,497,447)	(12,028,935)
<b>Gross profit</b>	<b>1,593,444</b>	<b>4,368,384</b>	<b>1,518,235</b>	<b>4,418,271</b>
Investment income	24,007	49,284	17,100	63,037
Other gains and losses	184,159	82,094	5,483	64,167
Finance costs	(868)	(4,441)		
Selling and distribution costs	(1,148,701)	(2,748,231)	(955,615)	(2,493,290)
Administrative expenses	(559,402)	(1,565,762)	(523,396)	(1,413,477)
Profit before tax	92,639	181,328	61,807	638,708
Income tax expense	(29,845)	(58,629)	(19,779)	(204,387)
<b>Total profit after tax for the period</b>	<b>62,794</b>	<b>122,699</b>	<b>42,028</b>	<b>434,321</b>
Profit for the period attributable to:				
Shareholders of the Company	62,794	122,699	42,028	434,321
Non-controlling interest	-	-	-	-
	<u>62,794</u>	<u>122,699</u>	<u>42,028</u>	<u>434,321</u>
Total comprehensive loss for the period attributable to:				
Shareholders of the Company	62,794	122,699	42,028	434,321
Non-controlling interest	-	-	-	-
	<u>62,794</u>	<u>122,699</u>	<u>42,028</u>	<u>434,321</u>
<b>Basic and diluted earnings per share (Kobo)</b>				
From continuing operations	5	10	4	36
From continuing and discontinuing operations	5	10	4	36

GlaxoSmithKline Consumer Nigeria Plc  
 Unaudited consolidated and separate statement of financial position  
 As at 30 September 2021

	GROUP			COMPANY		
	At 30 September, 2021	At 31 December 2020	At 30 September, 2020	At 30 September, 2021	At 31 December 2020	At 30 September, 2020
Notes	N'000	N'000	N'000	N'000	N'000	N'000
<b>Assets</b>						
<b>Non-current assets</b>						
Deferred tax asset	10.2	450,956	450,956	80,845	450,956	80,845
Property, plant and equipment	12	1,729,166	1,830,986	1,877,192	1,729,166	1,877,192
Right of use asset		45,045	95,971	46,879	45,045	46,879
Investment property		151,595	154,839	155,920	151,595	155,920
Investment in subsidiary	13	-	-	-	160	160
		<u>2,376,763</u>	<u>2,532,752</u>	<u>2,160,836</u>	<u>2,376,923</u>	<u>2,160,996</u>
<b>Current assets</b>						
Inventories	14	4,820,724	3,282,439	4,567,443	4,820,724	4,567,443
Trade and other receivables	15	5,876,418	4,649,954	6,518,118	5,876,418	6,518,118
Other assets	16	282,883	373,775	285,907	282,883	285,907
Cash and bank balances	17	10,136,715	12,896,742	8,699,132	10,136,715	8,699,132
Assets classified as asset held for sale		-	-	26,371	-	26,371
		<u>21,116,740</u>	<u>21,202,910</u>	<u>20,096,971</u>	<u>21,116,740</u>	<u>20,096,971</u>
<b>Total assets</b>		<b><u>23,493,503</u></b>	<b><u>23,735,662</u></b>	<b><u>22,257,807</u></b>	<b><u>23,493,663</u></b>	<b><u>22,257,967</u></b>
<b>Equity and liabilities</b>						
<b>Equity</b>						
Issued share capital	18.1	597,939	597,939	597,939	597,939	597,939
Share premium	18.2	51,395	51,395	51,395	51,395	51,395
Retained earnings		8,114,004	8,469,656	8,281,746	7,944,032	8,108,529
<b>Total equity</b>		<u>8,763,338</u>	<u>9,118,990</u>	<u>8,931,080</u>	<u>8,593,366</u>	<u>8,757,863</u>
<b>Non-current liabilities</b>						
Liability for share-based payments		30,730	30,730	-	30,730	-
<b>Total non-current liabilities</b>		<u>30,730</u>	<u>30,730</u>	<u>-</u>	<u>30,730</u>	<u>-</u>
<b>Current liabilities</b>						
Trade and other payables	19	14,525,111	13,579,643	13,025,746	14,708,989	13,213,141
Contract liabilities	20	59,951	105,606	61,774	59,951	61,774
Lease liabilities		20,140	106,610	-	20,140	-
Bank overdraft	17	-	11,160	-	-	-
Income tax payable	10.1	94,233	782,923	239,207	80,487	225,190
<b>Total current liabilities</b>		<u>14,699,435</u>	<u>14,585,942</u>	<u>13,326,727</u>	<u>14,869,567</u>	<u>13,500,105</u>
<b>Total liabilities</b>		<u>14,730,165</u>	<u>14,616,672</u>	<u>13,326,727</u>	<u>14,900,297</u>	<u>13,500,105</u>
<b>Total equity and liabilities</b>		<b><u>23,493,503</u></b>	<b><u>23,735,662</u></b>	<b><u>22,257,807</u></b>	<b><u>23,493,663</u></b>	<b><u>22,257,967</u></b>


The consolidated and separate financial statements were approved and authorised for issue by the Board of Directors on 22 Oct 2021 and signed on its behalf by:



Mr. Edmund C. Onuzo  
 Chairman  
 FRC/2015/IODN/00000011038



Mr. Olakunle Azeez Oyelana  
 Managing Director  
 FRC/2020/003/00000020395



Adewale Vincent  
 Senior Finance Manager  
 FRC/2018/ICAN/00000018187

**GlaxoSmithKline Consumer Nigeria Plc**  
**Unaudited consolidated and separate statement of changes in equity**  
**For the period ended 30 September 2021**

<b>Group</b>	<b>Share capital N'000</b>	<b>Share premium N'000</b>	<b>Retained earnings N'000</b>	<b>Total N'000</b>
At 1 January 2020	597,939	51,395	8,503,734	9,153,068
Profit for the period	-	-	434,321	434,321
Unclaimed dividend declared status barred	-	-	1,424	1,424
Dividend declared	-	-	(657,732)	(657,732)
At 30 September 2020	<u>597,939</u>	<u>51,395</u>	<u>8,281,747</u>	<u>8,931,081</u>
At 1 January 2020	597,939	51,395	8,503,734	9,153,068
Profit for the year	-	-	622,230	622,230
Unclaimed dividend declared status barred	-	-	1,424	1,424
Dividend declared	-	-	(657,732)	(657,732)
At 1 January 2021	<u>597,939</u>	<u>51,395</u>	<u>8,469,656</u>	<u>9,118,990</u>
Profit for the period	-	-	122,699	122,699
Unclaimed dividend declared status barred	-	-	-	-
Dividend declared	-	-	(478,351)	(478,351)
At 30 September 2021	<u><b>597,939</b></u>	<u><b>51,395</b></u>	<u><b>8,114,004</b></u>	<u><b>8,763,338</b></u>

<b>Company</b>	<b>Share capital N'000</b>	<b>Share premium N'000</b>	<b>Retained earnings N'000</b>	<b>Total N'000</b>
At 1 January 2020	597,939	51,395	8,331,092	8,980,426
Profit for the period	-	-	433,745	433,745
Unclaimed dividend declared status barred	-	-	1,424	1,424
Dividend declared	-	-	(657,732)	(657,732)
At 30 September 2020	<u>597,939</u>	<u>51,395</u>	<u>8,108,529</u>	<u>8,757,863</u>
At 1 January 2020	597,939	51,395	8,331,092	8,980,426
Profit for the year	-	-	623,014	623,014
Unclaimed dividend declared status barred	-	-	1,424	1,424
Dividend declared	-	-	(657,732)	(657,732)
At 1 January 2021	<u>597,939</u>	<u>51,395</u>	<u>8,297,798</u>	<u>8,947,132</u>
Profit for the period	-	-	124,585	124,585
Unclaimed dividend declared status barred	-	-	-	-
Dividend declared	-	-	(478,351)	(478,351)
At 30 September 2021	<u><b>597,939</b></u>	<u><b>51,395</b></u>	<u><b>7,944,032</b></u>	<u><b>8,593,366</b></u>

**GlaxoSmithKline Consumer Nigeria Plc**  
**Unaudited consolidated and separate statement of cash flows**  
**For the period ended 30 September 2021**

	Notes	GROUP			COMPANY		
		Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
		N'000	N'000	N'000	N'000	N'000	N'000
<b>Cash flows from operating activities</b>							
Profit for the year		122,699	622,230	434,321	124,585	623,014	433,745
Adjustment for:							
Income tax expense recognised in profit or loss		58,629	377,992	204,387	58,629	377,992	204,116
Depreciation (including investment property and right of use asset)	12	294,996	479,972	270,108	294,996	479,972	270,108
Loss/(gain) on disposal of property, plant and equipment	8	(5,195)	(4,162)	(3,364)	(5,195)	(4,162)	(3,364)
Interest on term deposits	7	(49,284)	(71,482)	(63,037)	(49,284)	(71,482)	(63,037)
Finance cost		4,441	39,150	-	4,441	39,150	-
Other adjustments to property, plant and equipment		38,282	67,219	40,849	38,282	67,219	40,849
Unrealised exchange loss/(gain) on operating activity		-	-	(4,429)	-	-	(4,429)
Share based payment expense		-	44,442	-	-	44,442	-
<b>Working capital adjustments:</b>							
Change in inventories		(1,538,285)	2,242,476	957,472	(1,538,285)	2,242,476	957,472
Change in trade receivables		(1,226,464)	2,030,458	326,736	(1,226,464)	2,030,458	325,844
Change in other assets		90,892	(142,540)	(219,114)	90,892	(143,432)	(219,114)
Change in contract liabilities		(45,655)	(51,229)	(95,061)	(45,655)	(51,229)	(95,061)
Change in trade and other payables		945,467	4,631,416	4,317,065	943,580	4,631,572	4,318,852
		(1,309,476)	10,265,942	6,165,933	(1,309,477)	10,265,990	6,165,981
Income tax paid	10.1	(747,318)	(477,971)	(477,971)	(747,318)	(477,971)	(477,971)
<b>Net cash generated by operating activities</b>		<b>(2,056,794)</b>	<b>9,787,971</b>	<b>5,687,962</b>	<b>(2,056,795)</b>	<b>9,788,019</b>	<b>5,688,010</b>
<b>Cash flows from investing activities</b>							
Proceeds from sale of property, plant and equipment		5,195	4,162	3,364	5,195	4,162	3,364
Interest received	7	49,284	71,482	63,037	49,284	71,482	63,037
Purchase of right of use asset		-	(181,343)	-	-	(181,343)	-
Purchase of property, plant and equipment	12	(177,289)	(140,061)	(109,735)	(177,289)	(140,061)	(109,735)
<b>Net cash flows generated by investing activities</b>		<b>(122,810)</b>	<b>(245,760)</b>	<b>(43,334)</b>	<b>(122,810)</b>	<b>(245,760)</b>	<b>(43,334)</b>
<b>Cash flows from financing activities</b>							
Share based payment settlement		-	(13,712)	-	-	(13,712)	-
Statute barred dividend received		-	1,424	1,424	-	1,424	1,424
Final dividends paid to shareholders of the Company		(478,351)	(352,437)	(657,732)	(478,351)	(352,437)	(657,732)
Lease liability paid		(90,911)	(106,218)	-	(90,911)	(106,218)	-
Proceed from lease liability		-	103,502	-	-	103,502	-
<b>Net cash flows used in financing activities</b>		<b>(569,262)</b>	<b>(367,441)</b>	<b>(656,308)</b>	<b>(569,262)</b>	<b>(367,441)</b>	<b>(656,308)</b>
Net increase in cash and cash equivalents		(2,748,866)	9,174,770	4,988,320	(2,748,867)	9,174,818	4,988,368
Cash and cash equivalents at 1 January		12,885,582	3,710,812	3,710,812	12,885,582	3,710,764	3,710,764
<b>Cash and cash equivalents at 30 September &amp; 31 December</b>	17	<b>10,136,716</b>	<b>12,885,582</b>	<b>8,699,132</b>	<b>10,136,715</b>	<b>12,885,582</b>	<b>8,699,132</b>

**GSK Consumer Nigeria Plc**  
**Shareholding Structure and Free Float Status**  
**Main Board**  
**Year End - 31 December**  
**Reporting Period - Period Ended 30 September 2021**  
**Share Price at end of reporting period: N6.10 (September 2020: N5.00)**

**Shareholding Structure/Free Float Status**

	30-Sep-21		30-Sep-20	
	Units	Percentage	Units	Percentage
Issued share capital	1,195,876,488	100%	1,195,876,488	100%
<b>Substantial Shareholdings (5% and above)</b>				
Setfirst Limited	326,593,793	27.3%	326,593,793	27.3%
Smithkline Beecham Limited	228,488,132	19.1%	228,488,132	19.1%
Stanbic Nominees Limited	67,888,100	5.7%	161,329,864	13.5%
Total Substantial Shareholdings	<u>622,970,025</u>	<u>52.1%</u>	<u>716,411,789</u>	<u>59.9%</u>
<b>Directors' Shareholdings (direct and indirect), excluding directors with substantial interests</b>				
Mr. Edmund C. Onuzo - direct	337,912	0.03%	113,210	0.01%
Mr. Edmund C. Onuzo - indirect	11,170	0.00%	11,170	0.00%
Mr. Samuel Kuye - direct	923	0.00%	923	0.00%
Mr. Samuel Kuye - indirect	93,750	0.01%	93,750	0.01%
Mr. Tunde Lemo - direct	0	0.00%	0	0.00%
Mrs. Oludewa Edodo-Thorpe - direct	31	0.00%	31	0.00%
Mrs. Oludewa Edodo-Thorpe - indirect	0	0.00%	31	0.00%
Total Directors' Shareholdings	<u>443,786</u>	<u>0.04%</u>	<u>219,115</u>	<u>0.02%</u>
<b>Other Influential Shareholdings</b>				
None	-	-	-	-
<b>Free Float in Units and Percentage</b>	572,462,677	48%	479,245,584	40%
<b>Free Float in Value</b>	<u><b>₦ 3,492,022,329.70</b></u>		<u><b>₦ 2,396,227,920.00</b></u>	

**Declaration**

(A) GSK Consumer Nigeria Plc with a free float percentage of 48% as at 30 September 2021, is compliant with The Exchange's free float requirements for companies listed on the Main Board.

(A) GSK Consumer Nigeria Plc with a free float percentage of 40% as at 30 September 2020, is compliant with The Exchange's free float requirements for companies listed on the Main Board.

**1.1 Corporate information**

The Company is a public limited liability company incorporated in 1971 and domiciled in Nigeria where its shares are publicly traded. 46.4% of the shares of the Company are held by Setfirst Limited and SmithKline Beecham Limited (both incorporated in the United Kingdom); and 53.6% by Nigerian shareholders. The ultimate parent and ultimate controlling party is GlaxoSmithKline Plc, United Kingdom (GSK Plc UK). GSK Plc UK controls the Company through Setfirst Limited and SmithKline Beecham Limited.

The registered office of the Company is located at 1 Industrial Avenue, Ilupeju, Lagos.

The principal activities of the company are manufacturing, marketing and distribution of consumer healthcare and pharmaceutical products.

The consolidated financial statements of the Group for the period ended 30 September 2021 comprise the result and the financial position of GlaxoSmithKline Consumer Nigeria Plc (the Company) and its wholly owned subsidiary– Winster Pharmaceuticals Limited which has no turnover for the current year following the sale of its only product to a third party on 30 April 2012.

**Securities Trading Policy**

In compliance with Rule 17.15 Disclosure of Dealings in Issuers' Shares, Rulebook of the Exchange 2015 (Issuers Rule) Glaxosmithkline Consumer Nigeria Plc (the Company) maintains effective Security Trading Policy which guides Directors, Audit Committee members, employees and all individuals categorized as insiders as to their dealing in the Company's shares. The Policy is regularly reviewed and updated by the Board. The Company has made specific inquiries of all the directors and other insiders and is not aware of any infringement of the policy during the period.

These consolidated and separate financial statements for the period ended 30 September 2021 have been approved for issue by the directors on 22 October, 2021.

**2.1 New and amended IFRS Standards that are effective for the current year**

**i) Impact of the initial application of Interest Rate Benchmark Reform amendments to IFRS 9 and IFRS 7.**

In September 2019, the IASB issued Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS 7). These amendments modify specific hedge accounting requirements to allow hedge accounting to continue for affected hedges during the period of uncertainty before the hedged items or hedging instruments affected by the current interest rate benchmarks are amended as a result of the on-going interest rate benchmark reforms.

The amendments also introduce new disclosure requirements to IFRS 7 for hedging relationships that are subject to the exceptions introduced by the amendments to IFRS 9. The new disclosure requirements are presented in note 63(c)(ii).

The Directors have reviewed the amendments to the IFRS and are of the opinion that this has no material impact on the Group's consolidated financial statements

**ii) Impact of the initial application of Covid-19-Related Rent Concessions Amendment to IFRS 16**

In May 2020, the IASB issued Covid-19-Related Rent Concessions (Amendment to IFRS 16) that provides practical relief to lessees in accounting for rent concessions occurring as a direct consequence of COVID-19, by introducing a practical expedient to IFRS 16. The practical expedient permits a lessee to elect not to assess whether a COVID19-related rent concession is a lease modification. A lessee that makes this election shall account for any change in lease payments resulting from the COVID-19-related rent concession the same way it would account for the change applying IFRS 16 if the change were not a lease modification.

The practical expedient applies only to rent concessions occurring as a direct consequence of COVID-19 and only if all of the following conditions are met:

- The change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;
- Any reduction in lease payments affects only payments originally due on or before 30 September 2021 (a rent concession meets this condition if it results in reduced lease payments on or before 30 September 2021 and increased lease payments that extend beyond 30 September 2021); and
- There is no substantive change to other terms and conditions of the lease.

The Directors have reviewed the amendments to the IFRS and are of the opinion that this has no material impact on the Group's consolidated financial statements

**iii) Impact of the initial application of other new and amended IFRS Standards that are effective for the current year**

In the current year, the Group has applied the below amendments to IFRS Standards and Interpretations issued by the Board that are effective for an annual period that begins on or after 1 January 2020. Their adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements.

**iv) Amendments to References to the Conceptual Framework in IFRS Standards**

The Group has adopted the amendments included in Amendments to References to the Conceptual Framework in IFRS Standards for the first time in the current year. The amendments include consequential amendments to affected Standards so that they refer to the new Framework. Not all amendments, however, update those pronouncements with regard to references to and quotes from the Framework so that they refer to the revised Conceptual Framework. Some pronouncements are only updated to indicate which version of the Framework they are referencing to (the IASC Framework adopted by the IASB in 2001, the IASB Framework of 2010, or the new revised Framework of 2018) or to indicate that definitions in the Standard have not been updated with the new definitions developed in the revised Conceptual Framework.

The Standards which are amended are IFRS 2, IFRS 3, IFRS 6, IFRS 14, IAS 1, IAS 8, IAS 34, IAS 37, IAS 38, IFRIC 12, IFRIC 19, IFRIC 20, IFRIC 22, and SIC-32.

**v) Amendments to IFRS 3 - Definition of a business**

The Group has adopted the amendments to IFRS 3 for the first time in the current year. The amendments clarify that while businesses usually have outputs, outputs are not required for an integrated set of activities and assets to qualify as a business. To be considered a business an acquired set of activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs.

The amendments remove the assessment of whether market participants are capable of replacing any missing inputs or processes and continuing to produce outputs. The amendments also introduce additional guidance that helps to determine whether a substantive process has been acquired. The amendments introduce an optional concentration test that permits a simplified assessment of whether an acquired set of activities and assets is not a business. Under the optional concentration test, the acquired set of activities and assets is not a business if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar assets. The amendments are applied prospectively to all business combinations and asset acquisitions for which the acquisition date is on or after 1 January 2020.

**vi) Amendments to IAS 1 and IAS 8 - Definition of material**

The Group has adopted the amendments to IAS 1 and IAS 8 for the first time in the current year. The amendments make the definition of material in IAS 1 easier to understand and are not intended to alter the underlying concept of materiality in IFRS Standards. The concept of 'obscuring' material information with immaterial information has been included as part of the new definition.

The threshold for materiality influencing users has been changed from 'could influence' to 'could reasonably be expected to influence'. The definition of material in IAS 8 has been replaced by a reference to the definition of material in IAS 1. In addition, the IASB amended other Standards and the Conceptual Framework that contain a definition of 'material' or refer to the term 'material' to ensure consistency.

The Directors have reviewed the amendments to the IFRS and are of the opinion that this has no material impact on the Group's consolidated financial statements.

**2.2 New and revised IFRSs Standards in issue but not yet effective**

At the date of authorisation of these financial statements, the Group has not applied the following new and revised IFRS Standards that have been issued but are not yet effective.

IFRS 17	Insurance Contracts
IFRS 10 and IAS 28 (amendments)	Sale or Contribution of Assets between an Investor and its Associates or Joint Ventures
Amendments to IAS 1	Classification of Liabilities as Current or Non-current
Amendments to IFRS 3	Reference to the Conceptual Framework
Amendments to IAS 16	Property, Plant and Equipment—Proceeds before Intended Use
Amendments to IAS 37	Onerous Contracts – Cost of Fulfilling a Contract
Annual Improvements to IFRS Standards 2018-2020 Cycle	Amendments to IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 9 Financial Instruments, IFRS 16 Leases, and IAS 41 Agriculture

The directors do not expect that the adoption of the Standards listed above will have a material impact on the financial statements of the Group in future periods.

**i) IFRS 17 Insurance Contracts**

IFRS 17 establishes the principles for the recognition, measurement, presentation and disclosure of insurance contracts and supersedes IFRS 4 Insurance Contracts. IFRS 17 outlines a general model, which is modified for insurance contracts with direct participation features, described as the variable fee approach. The general model is simplified if certain criteria are met by measuring the liability for remaining coverage using the premium allocation approach.

The general model uses current assumptions to estimate the amount, timing and uncertainty of future cash flows and it explicitly measures the cost of that uncertainty. It takes into account market interest rates and the impact of policyholders' options and guarantees.

In June 2020, the IASB issued Amendments to IFRS 17 to address concerns and implementation challenges that were identified after IFRS 17 was published. The amendments defer the date of initial application of IFRS 17 (incorporating the amendments) to annual reporting periods beginning on or after 1 January 2023. At the same time, the IASB issued Extension of the Temporary Exemption from Applying IFRS 9 (Amendments to IFRS 4) that extends the fixed expiry date of the temporary exemption from applying IFRS 9 in IFRS 4 to annual reporting periods beginning on or after 1 January 2023.

**ii) Amendments to IFRS 10 and IAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture**

The amendments to IFRS 10 and IAS 28 deal with situations where there is a sale or contribution of assets between an investor and its associate or joint venture. Specifically, the amendments state that gains or losses resulting from the loss of control of a subsidiary that does not contain a business in a transaction with an associate or a joint venture that is accounted for using the equity method, are recognised in the parent's profit or loss only to the extent of the unrelated investors' interests in that associate or joint venture. Similarly, gains and losses resulting from the remeasurement of investments retained in any former subsidiary (that has become an associate or a joint venture that is accounted for using the equity method) to fair value are recognised in the former parent's profit or loss only to the extent of the unrelated investors' interests in the new associate or joint venture.

The effective date of amendments has yet to be set by the IASB; however, earlier application of the amendments is permitted.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**iii) Amendments to IAS 1 – Classification of Liabilities as Current or Non-current**

The amendments to IAS 1 affect only the presentation of liabilities as current or non-current in the statement of financial position and not the amount or timing of recognition of any asset, liability, income or expenses, or the information disclosed about those items.

The amendments clarify that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of 'settlement' to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services.

The amendments are applied retrospectively for annual periods beginning on or after 1 January 2023, with early application permitted.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**iv) Amendments to IFRS 3 – Reference to the Conceptual Framework**

The amendments update IFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework. They also add to IFRS 3 a requirement that, for obligations within the scope of IAS 37, an acquirer applies IAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies, the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. Finally, the amendments add an explicit statement that an acquirer does not recognise contingent assets acquired in a business combination.

The amendments are effective for business combinations for which the date of acquisition is on or after the beginning of the first annual period beginning on or after 1 January 2022. Early application is permitted if an entity also applies all other updated references (published together with the updated Conceptual Framework) at the same time or earlier.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**v) Amendments to IAS 16 – Property, Plant and Equipment—Proceeds before Intended Use**

The amendments prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced before that asset is available for use, i.e. proceeds while bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Consequently, an entity recognises such sales proceeds and related costs in profit or loss. The entity measures the cost of those items in accordance with IAS 2 Inventories.



**GlaxoSmithKline Consumer Nigeria Plc**  
**Notes to the consolidated and separate financial statements**  
**For the period ended 30 September 2021**

The amendments are applied retrospectively, but only to items of property, plant and equipment that are brought to the location and condition necessary for them to be capable of operating in the manner intended by management on or after the beginning of the earliest period presented in the financial statements in which the entity first applies the amendments.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**vi) Amendments to IAS 37 – Onerous Contracts—Cost of Fulfilling a Contract**

The amendments specify that the 'cost of fulfilling' a contract comprises the 'costs that relate directly to the contract'. Costs that relate directly to a contract consist of both the incremental costs of fulfilling that contract (examples would be direct labour or materials) and an allocation of other costs that relate directly to fulfilling contracts (an example would be the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract).

The amendments are effective for annual periods beginning on or after 1 January 2022, with early application permitted.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**vii) Annual Improvements to IFRS Standards 2018–2020**

The Annual Improvements include amendments to four Standards.

- *IFRS 1 First-time Adoption of International Financial Reporting Standards*

The amendment provides additional relief to a subsidiary which becomes a first-time adopter later than its parent in respect of accounting for cumulative translation differences.

- *IFRS 9 Financial Instruments*

The amendment clarifies that in applying the '10 per cent' test to assess whether to derecognise a financial liability, an entity includes only fees paid or received between the entity (the borrower) and the lender, including fees paid or received by either the entity or the lender on the other's behalf.

- *IFRS 16 Leases*

The amendment removes the illustration of the reimbursement of leasehold improvements.

- *IAS 41 Agriculture*

The amendment removes the requirement in IAS 41 for entities to exclude cash flows for taxation when measuring fair value. This aligns the fair value measurement in IAS 41 with the requirements of IFRS 13 Fair Value Measurement to use internally consistent cash flows and discount rates and enables preparers to determine whether to use pretax or post-tax cash flows and discount rates for the most appropriate fair value measurement.

The amendments are effective for annual periods beginning on or after 1 January 2022, with early application permitted.

The directors of the Group do not anticipate that the application of the amendments in the future will have an impact on the Group's consolidated financial statements.

**3 Summary of significant accounting policies**

The following are the significant accounting policies applied by the Group in preparing its consolidated and separate financial statements:

**3.1 Reclassification**

Certain reclassifications have been made to prior year's financial statements to aid comparability with the current year's financial statements. This reclassification has had no impact on prior year's reported position.

**3.2 Statement of compliance**

The consolidated and separate financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB) that are effective at 31 December, 2020 and the requirements of the Companies and Allied Matters Act (CAMA) of Nigeria and Finance Reporting Council (FRC) Act of Nigeria.

**3.3 Basis of preparation**

The consolidated and separate financial statements have been prepared on a historical cost basis and are presented in Naira. All values are rounded to the nearest thousand (N'000), except when otherwise indicated.

**3.4 Basis of consolidation**

The consolidated and separate financial statements comprise the financial statements of the Company and its subsidiary (Winster Pharmaceutical Limited) as at 31 December 2020. Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The Group applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair values of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The Group recognises any non-controlling interest in the acquiree on an acquisition-by-acquisition basis, either at fair value or at the non-controlling interest's proportionate share of the recognised amounts of acquiree's identifiable net assets.

Acquisition-related costs are expensed as incurred. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is re-measured to fair value at the acquisition date; any gains or losses arising from such re-measurement are recognised in profit or loss.

Any contingent consideration to be transferred by the Group is recognised at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration that is deemed to be an asset or liability is recognised in accordance with IAS 39 either in profit or loss or as a change to other comprehensive income. Contingent consideration that is classified as equity is not re-measured, and its subsequent settlement is accounted for within equity.

Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated. When necessary, amounts reported by subsidiaries have been adjusted to conform with the Group's accounting policies.

Transactions with non-controlling interests that do not result in loss of control are accounted for as equity transactions – that is, as transactions with the owners in their capacity as owners. The difference between fair value of any consideration paid and the relevant share acquired of the carrying value of net assets of the subsidiary is recorded in equity. Gains or losses on disposals to non-controlling interests are also recorded in equity.

When the Group ceases to have control, any retained interest in the entity is remeasured to its fair value at the date when control is lost, with the change in carrying amount recognised in profit or loss. The fair value is the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss.

The investments in subsidiary is valued at cost within the Company financial statements.

### 3.5 Business combinations

Business combinations are accounted for using the acquisition accounting method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at acquisition date. The consideration transferred is measured at fair value and includes the fair value of any contingent consideration. Where the consideration transferred, together with the non-controlling interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. The costs of acquisition are charged to the income statement in the period in which they are incurred. Where not all of the equity of a subsidiary is acquired the noncontrolling interest is recognised either at fair value or at the non-controlling interest's share of the net assets of the subsidiary, on a case-by-case basis. Changes in the Group's ownership percentage of subsidiaries are accounted for within equity.

### 3.6 Goodwill

Goodwill arising on an acquisition of a business is carried at cost as established at the date of acquisition of the business less accumulated impairment losses, if any.

For the purposes of impairment testing, goodwill is allocated to each of the Group's cash-generating units (or groups of cash-generating units) that is expected to benefit from the synergies of the combination.

A cash-generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

### 3.7 Interests in joint operations

A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

When a group entity undertakes its activities under joint operations, the Group as a joint operator recognises in relation to its interest in a joint operation:

- its assets, including its share of any assets held jointly;
- its liabilities, including its share of any liabilities incurred jointly;
- its revenue from the sale of its share of the output arising from the joint operation;
- its share of the revenue from the sale of the output by the joint operation; and
- its expenses, including its share of any expenses incurred jointly.

The Group accounts for the assets, liabilities, revenues and expenses relating to its interest in a joint operation in accordance with the IFRSs applicable to the particular assets, liabilities, revenues and expenses.

When a group entity transacts with a joint operation in which a group entity is a joint operator (such as a sale or contribution of assets), the Group is considered to be conducting the transaction with the other parties to the joint operation, and gains and losses resulting from the transactions are recognised in the Group's consolidated and separate financial statements only to the extent of other parties' interests in the joint operation.

When a group entity transacts with a joint operation in which a group entity is a joint operator (such as a purchase of assets), the Group does not recognise its share of the gains and losses until it resells those assets to a third party.

### 3.8 Revenue recognition

Revenue is recognised by applying a five-step approach:

- Identify the contract
- Identify the separate performance obligations in the contract
- Determine the transaction price
- Allocate the transaction price to separate performance obligations
- Recognise revenue when (or as) each performance obligation is satisfied

#### 3.8.1 Identify the contract

Any agreement that creates enforceable rights and obligations is a contract. This covers revenue arising from contracts for:

- (a) Sale of the Groups products to retail customers, wholesalers or distributors;
- (b) Sale of products under contract manufacturing agreements;
- (c) Licences of GSK intellectual property;
- (d) Divestments of PP&E and intangible assets.

It does not cover revenue arising on sales of businesses or from collaboration agreements.

#### 3.8.2 Identify the separate performance obligations in the contract

Performance obligations are the explicit or implicit promises made to the customer or licensee in a contract. In a multi-element arrangement, it is necessary to determine if the promises made are distinct from each other or should be accounted for together as a bundle.

#### 3.8.3 Determine the transaction price

The transaction price is the amount of consideration that GSK is entitled to for the transfer of goods or services.

The price may include variable consideration where either

- uncollected revenue is contingent on future events occurring, such as meeting a sales milestone; or
- GSK's ability to retain revenue already invoiced or collected is contingent on future events not occurring, such as retrospective rebates being awarded by GSK or products being returned by the customer.

Variable consideration is estimated and recognised as revenue when it is highly probable that a significant reversal of the cumulative revenue recognised will not occur in future periods.

#### 3.8.4 Allocate the transaction price to separate performance obligations

The total consideration in a contract is divided between each of the distinct performance obligations in that contract on the basis of the standalone selling price of each.

#### 3.8.5 Recognise revenue when (or as) each performance obligation is satisfied

Revenue is recognised in the Income Statement when or as GSK fulfils its performance obligations. In the case of sale of products or divestment of other assets, this is when control of the products or assets has been transferred to the customer or buyer. In the case of services, the obligation is satisfied over the period of provision of the services.

#### Dividend and Interest income

Dividends are recognised when the Group's right to receive payment has been established, i.e. when the paying entity is irrevocably committed to paying the dividend which may be only on payment date or on approval by the shareholders of the dividend-paying entity

#### Rental Income

Rental and interest income are recognised when the Group's right to receive payment has been established, i.e. when the paying entity is irrevocably committed to paying the rental or interest income

### 3.9 Foreign currencies

#### (i) Functional and presentation currency

The Group measures the items in its financial statements using the currency of the primary economic environment in which it operates (the functional currency); the financial statements are presented in Nigerian Naira which is the Group's presentation and functional currencies.

#### (ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange ruling at the reporting date. All differences are recognised in profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

### 3.10 Taxes

#### Current income tax

The current income tax liabilities for the current period are measured at the amount expected to be paid to the taxation authorities. The tax rates and tax laws used to compute the amount are determined in accordance with the Companies Income Tax Act (CITA), CITA is assessed at 30% of the adjusted profit while Education tax is assessed at 2% of the assessable profits.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

#### Deferred tax

Deferred tax is provided using the liability method on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax liabilities are recognised for all taxable temporary differences, except:

- Where the deferred tax liability arises from the initial recognition of goodwill or of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or
- In respect of taxable temporary differences associated with investments in subsidiary where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss. Deferred tax items are recognised in correlation to the underlying transaction either in other comprehensive income or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off tax assets against tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

### 3.11 Property, plant and equipment

Property, plant and equipment are stated at cost of purchase or construction, less accumulated depreciation and accumulated impairment loss if any. Such cost includes the cost of replacing component parts of the property, plant and equipment. When significant parts of property, plant and equipment are required to be replaced at intervals, the Group derecognises the replaced part, and recognises the new part with its own associated useful life and depreciation. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the profit or loss as incurred.

Depreciation on the categories of property, plant and equipment is calculated to write off the cost less the residual value of the asset, using the straight-line basis, over the assets' expected useful life. The normal expected useful life for the major categories of property, plant and equipment are:

- Leasehold land	Over the life of the lease
- Buildings	Lower of lease term or 50 years
- Plant and machinery	10 to 15 years
- Furniture, fittings and equipment	4 to 7 years
- Motor vehicles	4 years

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the profit or loss when the asset is derecognised.

The assets' residual values, useful lives and methods of depreciation are reviewed at the end of each reporting period and adjusted prospectively, if appropriate.

### 3.12 Leases

The determination of whether an arrangement is, or contains, a lease is based on the substance of the arrangement at the inception date, whether fulfilment of the arrangement is dependent on the use of a specific asset or assets or the arrangement conveys a right to use the asset, even if that right is not explicitly specified in an arrangement.

Operating lease payments are recognised as an operating expense in the profit or loss on a straight-line basis over the lease term.

#### **Group as a lessor**

Leases in which the Group does not transfer substantially all the risks and benefits of ownership of the asset are classified as operating leases, all other leases are classified as finance leases. Initial direct costs incurred in negotiating an operating lease are added to the carrying amount of the leased asset and recognized over the lease term on the same basis as rental income. Contingent rents are recognized as revenue in the period in which they are earned.

### **3.13 Financial instruments — initial recognition and subsequent measurement**

A financial instrument is any contract that gives rise to both a financial asset of one entity and a financial liability or equity interest of another entity.

#### **3.13.1 Financial asset**

A financial asset is any asset that is:

- cash;
- an equity instrument of another entity;
- a contractual right to receive cash or another financial asset (e.g. receivables); or
- a contractual right to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to GSK (e.g. derivatives resulting in an asset, bonds and investments)

#### **3.13.2 Financial liability**

A financial liability is any liability that is:

- a contractual obligation to deliver cash or another financial asset (e.g. payable); or
- a contractual obligation to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the Group (e.g. payables, loans and derivatives resulting in a liability).

#### **3.13.3 Amortised cost**

Most of GSK's financial assets and liabilities are measured at amortised cost, including most trade receivables and trade payables. The amortised cost of a financial asset or financial liability is the amount at which the asset or liability is measured at initial recognition minus principal repayments to date, and minus any reduction for impairment.

If there is a difference between the initial amount and the maturity amount (arising from reasons other than impairment), amortised cost will also be plus or minus the cumulative amortisation using the effective interest method.

#### **3.13.4 Effective interest method**

The effective interest method calculates amortised cost by allocating the interest payment or expense over the relevant period. This calculation only applies if a premium has been paid or a discount received. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument. When estimating cash flows, all contractual terms are considered but expected future credit losses are not taken into account unless the financial instrument is credit-impaired.

#### **3.13.5 Expected credit loss (ECL)**

The expected credit loss is the difference between the cash flows due under the contract and the cash flows expected to be received, discounted at the original effective interest rate. An expected credit loss allowance is similar to an impairment provision.

#### **3.13.6 Expected credit loss allowance**

An allowance for expected credit losses (ECLs) on all financial assets measured at amortised cost, e.g. most trade and other receivables, is set up through the Income Statement at initial recognition of the asset. The ECL is deducted from the carrying value of the asset on the balance sheet. Subsequent movements in the ECL (including release of the ECL if the asset is recovered in full) are reported in the Income Statement.

All ECL (impairment) allowances must be reviewed at least quarterly.

In applying the IFRS 9 impairment requirements, an entity needs to apply one of the following approaches:

- The simplified approach, which will be applied to trade receivables.
- The general approach, which will be applied to other receivables, including royalty receivables, and to loan assets and investments in debt securities.

##### **(a) The simplified impairment approach**

The simplified approach applied to trade receivables requires the recognition of lifetime ECLs at all times. GSK entities use a provision matrix as a practical expedient for determining ECLs on trade receivables, including non-overdue balances. The provision matrix should incorporate forward-looking information into historical customer default rates and, where appropriate, group receivables into customer segments that have similar loss patterns, such as public (government) and private customers

##### **(b) The general impairment approach**

Under the general approach, prior to an asset actually being credit-impaired, entities recognise expected credit losses (ECLs) in two stages. For assets for which there has not been a significant increase in credit risk since initial recognition (i.e. 'good' exposures), entities are required to provide for ECLs that would result from default events that are possible within the next 12 months (a 12-month ECL).

For assets for which there has been a significant increase in credit risk since initial recognition, a loss allowance for ECLs expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL), is required.

Indicators of a significant increase in credit risk include:

- An actual or expected significant change in the financial asset's external or internal credit rating;
- Existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant change in the debtor's ability to meet its debt obligations, such as an increase in interest rates or a significant increase in unemployment rates;
- An actual or expected significant change in the operating results of the debtor;
- Significant increases in credit risk on other financial instruments of the debtor;
- An actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant change in the debtor's ability to meet its debt obligations, such as a decline in the demand for the debtor's sales product because of a shift in technology;
- Expected changes in the loan documentation (i.e. changes in contract terms) including an expected breach of contract that may lead to covenant waivers or amendments, interest payment holidays, interest rate step-ups, requiring additional collateral or guarantees, or other changes to the contractual framework of the instrument;
- Significant changes in the expected performance and behaviour of the debtor, including changes in the payment status of debtor in the group (e.g., an increase in the expected number or extent of delayed contractual payments); and
- Past due information on debtors.

For current assets (expected to be recovered in less than 12 months), there will be no difference between the 12-month ECL and the lifetime ECL.

##### **(c) Credit-impaired assets**

Under both approaches, when the asset becomes credit impaired due to the occurrence of a 'loss event' additional expected credit loss should be recognised. Loss events may include:

- Significant financial difficulty of the customer;
- It becoming probable that the customer will enter bankruptcy or other financial reorganisation;
- A breach of contract such as default or past due event;

If the credit-impaired asset is interest-bearing, interest should be calculated on the net asset balance, i.e. the gross amount adjusted for ECLs.

**(d) Asset write-off**

The asset, or a portion thereof, is written off through utilisation of the ECL allowance once there is no reasonable expectation of recovery. This point is a matter of judgement that will depend on facts and circumstances. Indicators include:

- Status of the debtor e.g. liquidation;
- Number of days past due or number of days since the last payment was received.

**3.14 Inventories**

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and related production overheads (based on normal operating capacity). It excludes borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses.

**3.15 Cash and bank balances**

Cash and bank balances in the statement of financial position comprise cash at banks and on hand and short-term deposits with a maturity of three months or less. For the purpose of the consolidated and separate statement of cash flows, cash and cash equivalents consist of cash and short-term deposits as defined above, net of outstanding bank overdrafts.

**3.16 Impairment of non-current assets**

The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs to sell, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used.

The Group bases its impairment calculation on detailed budgets and forecast calculations which are prepared separately for each of the Group's cash-generating units to which the individual assets are allocated. These budgets and forecast calculations are generally covering a period of five years. For longer periods, a long term growth rate is calculated and applied to project future cash flows after the fifth year. Impairment losses of continuing operations, including impairment on inventories, are recognised in the profit or loss in those expense categories consistent with the function of the impaired asset.

An assessment is made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the Group estimates the asset's or cash-generating unit's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the profit or loss.

**3.17 Pensions and other post employment benefits**

The Group operates a gratuity scheme for a certain category of employees and a pension fund scheme for the benefit of all of its employees.

(i) **Pension fund scheme:** the Group in line with the provisions of the Pension Reform Act 2014, which repealed the Pension Reform Act No. 2 of 2004, has a defined contribution pension scheme for its employees. Contributions to the scheme are funded through payroll deductions while the Group's contribution is charged to the profit or loss. The Group contributes 10% while the employees contribute 8% of the pensionable emoluments.

(ii) **Bonus plan:** the Group recognises a liability and an expense for bonuses, based on a formula that takes into consideration the profit for the year and the performance rating of each staff. The Group recognises a provision where contractually obliged or where there is a past practice that has created a constructive obligation.

**3.18 Segment report**

The Group defines its segments on the basis of business sectors. The segments are reported in a manner consistent with internal reporting guidelines provided by the GSK Group (UK).

The Group's segment report has been prepared in accordance with IFRS 8 based on operating segment and product ownership identified by the group and takes geographical reporting into considerations. The operating segments consist of Pharmaceuticals (Prescription drugs and vaccines) and Consumer Healthcare (Oral care, OTC medicines and nutritional healthcare). The Group's management reporting process allocates segment revenue and related cost on the basis of each operating segment. There are no sales between the operating segments.

**3.19 Provisions**

Provisions are recognised when the Group has a present legal or constructive obligation as a result of a past event, and it is probable that the Group will be required to settle that obligation and the amount has been reliably estimated.

**3.20 Share-based payments**

**Share-based payment transactions of the Group**

The Group does not have an equity settled share option plan.

For cash-settled share-based payments, a liability is recognised for the goods or services acquired, measured initially at the fair value of the liability. At each reporting date until the liability is settled, and at the date of settlement, the fair value of the liability is remeasured, with any changes in fair value recognised in profit or loss for the year.

**3.21 Borrowings**

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the income statement over the period of the borrowing using the effective interest method.

Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down.

**3.21.1 Borrowing cost**

General and specific borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

**3.22 Dividend**

Dividend distribution to the Company's shareholders is recognised as a liability in the Group's financial statements in the period in which the dividends are approved by the Company's shareholders.

**3.23 Share capital**

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new ordinary shares are shown in equity as a deduction, net of tax, from the proceeds.

**3.24 Disposal groups held for sale**

Non-current assets (or disposal groups) are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs to sell.

**3.25 Research and development**

Research and development expenditure is charged to the income statement in the period in which it is incurred. Property, plant and equipment used for research and development is capitalised and depreciated in accordance with the Group's policy.

**3.26 Investment property**

Investment properties are properties held to earn rentals and/or for capital appreciation (including property under construction for such purposes). Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are measured at cost. All of the Group's property interests held under operating leases to earn rentals or for capital appreciation purposes are accounted for as investment properties and are measured using the fair value model. Gains and losses arising from changes in the fair value of investment properties are included in profit or loss in the period in which they arise.

An investment property is derecognised upon disposal or when the investment property is permanently withdrawn from use and no future economic benefits are expected from the disposal. Any gain or loss arising on derecognition of the property (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in profit or loss in the period in which the property is derecognised.

**4. Significant accounting judgments, estimates and assumptions**

The preparation of the Group's consolidated and separate financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities, at the end of the reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

**Judgments**

In the process of applying the Group's accounting policies, management has made the following judgments, which have the most significant effect on the amounts recognised in the consolidated and separate financial statements:

**Going concern**

The Directors do not consider Winster Pharmaceutical Limited (the wholly owned subsidiary) to be a going concern. This is as a result of the sale of the Company's only product - Cafenol, to a third party on 30 April 2012. The implication of this is that the assets of the Company have been stated at their realisable values and liabilities are all treated as current.

**Revenue recognition**

In making their judgement, the directors considered the detailed criteria for the recognition of revenue set out in IFRS 15 and, in particular, whether the Group had transferred control of the goods to the customer. Following the detailed quantification of the Group's liability in respect of rectification work, and the agreed limitation on the customer's ability to require further work or to require replacement of the goods, the directors are satisfied that control has been transferred and that recognition of the revenue in the current year is appropriate, in conjunction with the recognition of an appropriate warranty provision for the rectification costs.

**Estimates and assumptions**

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the consolidated and separate financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

**Taxes**

Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range of international business relationships and the long-term nature and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. The Group establishes provisions, based on reasonable estimates, for possible consequences of audits by the tax authorities. The amount of such provisions is based on various factors, such as experience of previous tax audits and differing interpretations of tax regulations by the taxable entity and the responsible tax authority.

Deferred tax is provided on temporary differences between the tax bases of assets and liabilities and their carrying amounts, at the rates that have been enacted or substantively enacted as at the balance sheet date.

**Expected credit loss allowance**

An allowance for expected credit losses (ECLs) on all financial assets measured at amortised cost, e.g. most trade and other receivables, is set up through the Income Statement at initial recognition of the asset. The ECL is deducted from the carrying value of the asset on the balance sheet. The simplified approach applied to trade receivables requires the recognition of lifetime ECLs at all times. The Group uses a provision matrix as a practical expedient for determining ECLs on trade receivables, including non-overdue balances. The provision matrix incorporates forward-looking information into historical customer default rates and, where appropriate, group receivables into customer segments that have similar loss patterns, such as public (government) and private customers.

Under the general approach, prior to an asset actually being credit-impaired, entities recognise expected credit losses (ECLs) in two stages. For assets for which there has not been a significant increase in credit risk since initial recognition (i.e. 'good' exposures), entities are required to provide for ECLs that would result from default events that are possible within the next 12 months (a 12-month ECL). For assets for which there has been a significant increase in credit risk since initial recognition, a loss allowance for ECLs expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL), is required.

**Impairment testing**

Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available unobservable inputs that are developed based upon the best information available under the circumstances, which might include the Company's own data less incremental costs of disposing of the asset. The value in use calculation is based on a discounted cash flow (DCF) model. The cash flows are derived from the budget for the next five years for the entity and the next year for the manufacturing plant and do not include significant future investments that will enhance the performance of the assets of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes.

**Year end translation rate**

IAS 21 requires that at each reporting period, monetary assets and liabilities be translated using the closing rate. When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date. In prior years, translation of monetary assets and liabilities has been done using the central bank of Nigeria or Inter-bank rates.

During the year, the rate available to the company are shown below:

- The CBN rate
- Inter-bank rate and
- The GSK UK Group rate

In translating year end monetary assets and liabilities, inter-bank rates which represents the rate at which the company funded its foreign currency transactions have been utilised.

5 The following represents the Group and Company's revenue for the year from continuing operations excluding investment income

	Group & Company		
	Nine months ended 30 September, 2021 N'000	31 December 2020 N'000	Nine months ended 30 September, 2020 N'000
Revenue from the sale of goods - Local	16,304,126	21,227,652	16,447,206
Revenue from rendering of service - Export	148,456	67,697	-
	<b>16,452,582</b>	<b>21,295,249</b>	<b>16,447,206</b>

### 5.1 Segment information

#### Product and services from which reportable segments derive their revenue

The Chief Operating Decision Maker has been identified as the Management Team. For management purposes, the Group is organised into business units based on their products and has two reportable segments as follows:

Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines and nutritional healthcare; and Pharmaceuticals segment consisting of antibacterial, vaccines and prescription drugs.

Management team monitors the operating results of its operating units separately for the purpose of making decisions about resource allocation and performance assessment. The Agbara global manufacturing site produces goods for the consumer healthcare segment while pharmaceuticals are imported. Segment performance is evaluated based on revenue and operating profit or loss and is measured consistently with operating profit or loss in the consolidated and separate financial statements.

There are no sales between business segments.

The Group's reportable segments under IFRS 8 are Consumer Healthcare and Pharmaceuticals.

### 5.2 Segment revenue and results

The following is an analysis of the Group's revenue and results, assets and liabilities from continuing operations by reporting segment. Segment performance is measured based on revenue and operating profit, as management believes such information is the most relevant in evaluating results of segments relative to other entities.

Nine months ended 30 September, 2021	Consumer Healthcare	Pharmaceuticals	Non-Operating income	Total
	N'000	N'000	N'000	N'000
<b>Segment results</b>				
Revenue	5,765,511	10,687,071	-	16,452,582
Cost of sales	(3,292,795)	(8,791,403)	-	(12,084,198)
Gross profit	2,472,716	1,895,668	-	4,368,384
Operating expenses	(2,093,651)	(2,220,342)	-	(4,313,993)
Operating (loss)/profit	379,065	(324,674)	-	54,391
Investment income	-	-	49,284	49,284
Finance costs	(4,441)	-	-	(4,441)
Other gains and losses	(84,177)	166,271	-	82,094
<b>Profit/(loss) before tax</b>	<b>290,447</b>	<b>(158,403)</b>	<b>49,284</b>	<b>181,328</b>
<b>Segment assets &amp; liabilities</b>				
Non-current assets excluding deferred tax	1,925,807	-	-	1,925,807
Net additions to non-current assets, excluding deferred tax	-	-	-	-
Total non current assets excluding deferred tax	1,925,807	-	-	1,925,807
Current assets	15,380,383	5,736,357	-	21,116,740
<b>Total asset excluding deferred tax</b>	<b>17,306,190</b>	<b>5,736,357</b>	<b>-</b>	<b>23,042,547</b>
<b>Segment liabilities excluding deferred tax</b>	<b>4,760,828</b>	<b>9,938,607</b>	<b>-</b>	<b>14,699,435</b>

31 December 2020	Consumer Healthcare	Pharmaceuticals	Non-Operating income	Total
	N'000	N'000	N'000	N'000
<b>Segment results</b>				
Revenue	6,249,753	15,045,496	-	21,295,249
Cost of sales	(3,525,569)	(11,854,925)	-	(15,380,493)
Gross profit	2,724,184	3,190,572	-	5,914,756
Operating expenses	(2,279,895)	(2,833,682)	-	(5,113,577)
Operating (loss)/profit	444,289	356,890	-	801,179
Investment income	-	-	71,482	71,482
Finance costs	(39,150)	-	-	(39,150)
Other gains and losses	6,490	160,221	-	166,711
<b>Profit/(loss) before tax</b>	<b>411,629</b>	<b>517,111</b>	<b>71,482</b>	<b>1,000,222</b>
<b>Segment assets &amp; liabilities</b>				
Non-current assets excluding deferred tax	2,081,796	-	-	2,081,796
Total non current assets excluding deferred tax	2,081,796	-	-	2,081,796
Current assets	15,242,560	5,960,350	-	21,202,910
<b>Total asset excluding deferred tax</b>	<b>17,324,356</b>	<b>5,960,350</b>	<b>-</b>	<b>23,284,706</b>
<b>Segment liabilities excluding deferred tax</b>	<b>9,729,850</b>	<b>4,886,823</b>	<b>-</b>	<b>14,616,673</b>



GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

Nine months ended 30 September, 2020	Consumer Healthcare	Pharmaceuticals	Non-Operating income	Total
	N'000	N'000	N'000	N'000
<b>Segment results</b>				
Revenue	4,695,890	11,751,316	-	16,447,206
Cost of sales	(2,823,294)	(9,205,641)	-	(12,028,935)
Gross profit	1,872,596	2,545,675	-	4,418,271
Operating expenses	(1,644,802)	(2,261,965)	-	(3,906,767)
Operating (loss)/profit	227,794	283,710	-	511,504
Investment income	-	-	63,037	63,037
Other gains and losses	172,922	(112,119)	3,364	64,167
<b>Profit/(loss) before tax</b>	<b>400,716</b>	<b>171,591</b>	<b>66,401</b>	<b>638,708</b>
<b>Segment assets &amp; liabilities</b>				
Non-current assets excluding deferred tax	2,079,991	-	-	2,079,991
Total non current assets excluding deferred tax	2,079,991	-	-	2,079,991
Current assets	14,685,707	5,411,264	-	20,096,971
<b>Total asset excluding deferred tax</b>	<b>16,765,698</b>	<b>5,411,264</b>	<b>-</b>	<b>22,176,962</b>
<b>Segment liabilities excluding deferred tax</b>	<b>12,988,128</b>	<b>338,599</b>	<b>-</b>	<b>13,326,727</b>

The accounting policies of the segments are the same as the Group's accounting policies describe in Note 3. This is the measure reported to the management for the purpose of resources allocation and measurement

The accounting policies of the reporting segments are the same as the Group's accounting policies described in note 3. The segment reporting represents profit before tax earned by each segment without allocation of central administration cost, investment income and finance cost.

For the purpose of monitoring segments performance and allocating resources between segments :

- all assets are allocated to reportable segment other than deferred tax asset. Assets used by reportable segments are allocated on the basis of the revenues earned by individual reportable segments

- all liabilities are allocated to reportable segments other than current and deferred tax liabilities. Liabilities for which reportable segments are jointly liable are allocated in proportion to segments assets

6 The following represents the Group and Company's selling and administrative expenses.

	Group			Company		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
Payroll costs	797,352	1,065,845	820,323	797,352	1,065,845	820,323
Electricity, fuel & utility	66,304	59,298	47,884	66,304	59,298	47,884
Repairs and maintenance - vehicles	5,012	14,386	17,719	5,012	14,386	17,719
Repairs and maintenance - others	22,393	38,940	30,267	22,393	38,940	30,267
Insurance	18,840	34,777	24,014	18,840	34,777	24,014
Depreciation	96,573	90,352	65,085	96,573	90,352	65,085
Rent and rates	152,244	121,949	133,766	152,244	121,949	133,766
Security & facility expenses	38,262	11,128	13,430	38,262	11,128	13,430
Freight cost	223,001	226,713	143,426	223,001	226,713	143,426
Travel and expenses	50,893	27,409	25,223	50,893	27,409	25,223
Telecom cost	12,073	55,282	44,513	12,073	55,282	44,513
Audit fees	17,426	23,500	17,625	16,676	22,500	16,875
Consultancy	33,355	60,861	81,558	32,219	55,339	77,551
Advert and promotion	1,094,956	1,207,252	921,542	1,094,956	1,207,252	921,542
Bank charges	50,380	43,183	28,714	50,380	43,183	28,714
Other business expenses	118,368	105,027	74,585	118,368	105,027	74,585
Intercompany rechargeable expenses	1,461,942	1,854,181	1,294,272	1,461,942	1,854,181	1,294,272
Impairment of receivables	54,619	73,494	122,821	54,619	73,494	122,821
	<b>4,313,993</b>	<b>5,113,577</b>	<b>3,906,767</b>	<b>4,312,107</b>	<b>5,107,055</b>	<b>3,902,010</b>

5a	Group			Company		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
Expense by nature have been disclosed in the statement of comprehensive income as follows:						
Selling and distribution	2,748,231	3,519,762	2,493,290	2,748,231	3,519,762	2,493,290
Administrative expenses	1,565,762	1,593,815	1,413,477	1,563,876	1,587,293	1,408,720
	<b>4,313,993</b>	<b>5,113,577</b>	<b>3,906,767</b>	<b>4,312,107</b>	<b>5,107,055</b>	<b>3,902,010</b>

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

		Group & Company		
		Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
		N'000	N'000	N'000
<b>7</b>	<b>Investment income</b>			
	Interest income on short-term deposits	49,284	71,482	63,037
		<u>49,284</u>	<u>71,482</u>	<u>63,037</u>

		GROUP			COMPANY		
		Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
		N'000	N'000	N'000	N'000	N'000	N'000
<b>8</b>	<b>Other gains and losses</b>						
	Profit/(loss) from sale of property, plant and equipment	5,195	4,162	3,364	5,195	4,162	3,364
	Realised exchange foreign exchange losses	(8,542)	19,898	5,894	(8,542)	19,898	5,894
	Unrealised foreign exchange gains/(losses)	14,949	7,281	4,429	14,949	7,281	4,429
	<b>Provision no longer required:</b>						
	Trade receivables	59,398	71,573	114,360	59,398	71,573	114,360
	Other sundry (expense)/income	11,094	63,797	(63,880)	11,094	58,059	(69,484)
		<u>82,094</u>	<u>166,711</u>	<u>64,167</u>	<u>82,094</u>	<u>160,973</u>	<u>58,563</u>

**9 Expenses by nature**

Profit before tax from continuing operation has been arrived at after charging/(crediting):

		GROUP			COMPANY		
		Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
		N'000	N'000	N'000	N'000	N'000	N'000
	Audit fees	17,426	23,500	17,625	16,676	22,500	16,875
	Net impairment on receivables	(4,779)	1,921	122,821	(4,779)	1,921	122,821
	Depreciation	294,996	479,972	270,108	294,996	479,972	270,108
	Net foreign exchange (gain)/ loss	(6,407)	(27,179)	(10,323)	(6,407)	(27,179)	(10,323)

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

10 Taxes

Statement of financial position:

	GROUP			COMPANY		
	Nine months ended 30 September, 2021 N'000	31 December 2020 N'000	Nine months ended 30 September, 2020 N'000	Nine months ended 30 September, 2021 N'000	31 December 2020 N'000	Nine months ended 30 September, 2020 N'000
<b>10.1 Current tax liabilities:</b>						
At 1 January	782,923	512,791	512,791	769,177	499,045	499,045
<b>Tax charge in income statement:</b>						
Charge in the current year	58,629	748,103	204,387	58,629	748,103	204,116
Back duty assessment	-	-	-	-	-	-
	841,551	1,260,894	717,178	827,805	1,247,148	703,161
Company income tax paid	(52,014)	(39,216)	(39,216)	(52,014)	(39,216)	(39,216)
Education tax paid	(695,304)	(438,755)	(438,755)	(695,304)	(438,755)	(438,755)
Company income tax paid At 30 September & 31 December	<b>94,233</b>	<b>782,923</b>	<b>239,207</b>	<b>80,487</b>	<b>769,177</b>	<b>225,190</b>

10.2 Deferred tax balances:

Reflected in the statement of financial position as follows:

Deferred tax assets	(872,632)	(872,632)	(395,219)	(872,632)	(872,632)	(395,219)
Deferred tax liabilities	421,676	421,676	314,374	421,676	421,676	314,374
Deferred tax (asset)/liabilities	<b>(450,956)</b>	<b>(450,956)</b>	<b>(80,845)</b>	<b>(450,956)</b>	<b>(450,956)</b>	<b>(80,845)</b>

The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

	GROUP			COMPANY		
	Nine months ended 30 September, 2021 N'000	31 December 2020 N'000	Nine months ended 30 September, 2020 N'000	Nine months ended 30 September, 2021 N'000	31 December 2020 N'000	Nine months ended 30 September, 2020 N'000
<b>11 Earnings per share</b>						
Net profit attributable to ordinary equity holders of the parent from continuing operations	122,699	622,230	434,321	122,699	622,230	433,745
Net profit attributable to ordinary equity holders of the parent from continuing and discontinued operations	122,699	622,230	434,321	122,699	926,054	433,745
Weighted average number of ordinary shares for basic earnings per share	1,195,876	1,195,876	1,195,876	1,195,876	1,195,876	1,195,876
Basic and diluted earnings per share (kobo)- continuing operations	10	52	36	10	77	36
Basic and diluted earnings per share (kobo)- continuing and discontinued operations	10	52	36	10	77	36

There have been no transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these consolidated and separate financial statements. There are no potentially dilutive shares at the reporting date thus the Group's diluted earnings per share and basic earnings per share both have the same value.

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

12	Property, plant and equipment Group and Company	Leasehold land N'000	Buildings N'000	Plant and machinery N'000	Construction in progress N'000	Furniture, fittings and equipment N'000	Motor vehicles N'000	Total N'000
	<b>Cost:</b>							
	At 1 January 2020	461,796	493,369	1,929,229	108,439	939,460	311,249	4,243,541
	Additions	-	-	1,932	107,803	-	-	109,735
	Transfers	4,725	4,238	-	(49,679)	14,008	26,708	-
	Reclassification	(476)	(8,434)	644,566	-	(632,110)	(3,546)	-
	Adjustments	-	(998)	-	(39,851)	-	-	(40,849)
	Reclassification to asset held for sale	-	-	-	(26,371)	-	-	(26,371)
	Disposals	-	-	-	-	(2,023)	(34,330)	(36,352)
	<b>At 30 September 2020</b>	<b>466,045</b>	<b>488,174</b>	<b>2,575,726</b>	<b>100,341</b>	<b>319,335</b>	<b>300,082</b>	<b>4,249,704</b>
	At 1 January 2020	461,796	493,369	1,929,229	108,439	939,460	311,249	4,243,541
	Additions	-	-	1,932	59,063	-	79,066	140,061
	Transfers	4,725	4,238	26,708	(49,679)	14,008	-	-
	Reclassification	(476)	(8,434)	644,566	-	(632,110)	(3,546)	-
	Adjustments	-	-	(998)	(39,850)	-	-	(40,848)
	Reclassification to asset held for sale	-	-	-	(26,371)	-	-	(26,371)
	Disposals	-	-	-	-	(2,636)	(38,735)	(41,371)
	<b>At 1 January 2021</b>	<b>461,796</b>	<b>489,172</b>	<b>2,601,437</b>	<b>51,601</b>	<b>318,722</b>	<b>348,035</b>	<b>4,275,012</b>
	Additions	-	-	-	19,807	-	157,482	177,289
	Transfers	-	-	-	-	-	-	-
	Adjustments	-	-	6,726	(71,408)	26,400	-	(38,282)
	Disposals	-	-	-	-	-	(42,658)	(42,658)
	<b>At 30 September 2021</b>	<b>461,796</b>	<b>489,172</b>	<b>2,608,162</b>	<b>(0)</b>	<b>345,122</b>	<b>462,859</b>	<b>4,371,360</b>
	<b>Depreciation:</b>							
	At 1 January 2020	136,413	53,912	1,536,568	-	280,588	173,305	2,180,785
	Charge for the year	5,631	7,328	164,885	-	11,347	38,887	228,078
	Disposals	(713)	676	(6,638)	-	(3,950)	10,624	0
	Adjustments	-	-	-	-	(2,022)	(34,330)	(36,352)
	<b>At 30 September 2020</b>	<b>141,332</b>	<b>61,916</b>	<b>1,694,815</b>	<b>-</b>	<b>285,963</b>	<b>188,486</b>	<b>2,372,512</b>
	At 1 January 2020	136,413	53,912	1,536,568	-	280,588	173,305	2,180,785
	Charge for the year	3,090	13,884	218,311	-	14,722	54,602	304,610
	Reclassification	(713)	679	(6,642)	-	(3,949)	10,624	-
	Disposals	-	-	-	-	(2,635)	(38,735)	(41,370)
	<b>At 1 January 2021</b>	<b>138,791</b>	<b>68,475</b>	<b>1,748,237</b>	<b>-</b>	<b>288,725</b>	<b>199,797</b>	<b>2,444,026</b>
	Charge for the period	5,562	7,175	156,514	-	9,255	62,321	240,826
	Disposals	-	-	-	-	-	(42,658)	(42,658)
	Adjustments	-	-	-	-	-	-	-
	<b>At 30 September 2021</b>	<b>144,352</b>	<b>75,650</b>	<b>1,904,751</b>	<b>-</b>	<b>297,980</b>	<b>219,460</b>	<b>2,642,194</b>
	<b>Net book value:</b>							
	<b>At 30 September 2021</b>	<b>317,444</b>	<b>413,522</b>	<b>703,411</b>	<b>0</b>	<b>47,142</b>	<b>243,399</b>	<b>1,729,166</b>
	<b>At 31 December 2020</b>	<b>323,005</b>	<b>420,697</b>	<b>853,200</b>	<b>51,601</b>	<b>29,997</b>	<b>148,238</b>	<b>1,830,986</b>
	<b>At 30 September 2020</b>	<b>324,714</b>	<b>426,258</b>	<b>880,911</b>	<b>100,341</b>	<b>33,372</b>	<b>111,595</b>	<b>1,877,192</b>

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
<b>13 Investment in subsidiary</b>						
Investment in subsidiary	-	-	-	160	160	160

This represents investment in Winster Pharmaceuticals Limited, a wholly owned subsidiary company, which is measured at cost. Winster has no turnover for the current year following the sale of its only product to a third party in 2012. The results of the Company have been consolidated in these financial statements.

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
<b>14 Inventories</b>						
Raw materials and consumables	432,334	1,138,667	1,269,606	432,334	1,138,667	1,269,606
Work in progress	16,790	299,739	72,880	16,790	299,739	72,880
Finished goods	4,321,804	1,792,254	3,162,765	4,321,804	1,792,254	3,162,765
Engineering spares	49,796	51,779	62,192	49,796	51,779	62,192
<b>Total inventories</b>	<b>4,820,724</b>	<b>3,282,439</b>	<b>4,567,443</b>	<b>4,820,724</b>	<b>3,282,439</b>	<b>4,567,443</b>

	GROUP			GROUP		
	Nine months ended 30 September, 2021			Nine months ended 30 September, 2020		
	Consumer N'000	Pharma N'000	Total N'000	Consumer N'000	Pharma N'000	Total N'000
<b>14.1 Inventories - By Segment</b>						
Raw materials and consumables	432,334	-	432,334	1,269,606	-	1,269,606
Work in progress	16,790	-	16,790	72,880	-	72,880
Finished goods	1,861,700	2,460,104	4,321,804	1,062,587	2,100,178	3,162,765
Engineering spares	49,796	-	49,796	62,192	-	62,192
	<b>2,360,620</b>	<b>2,460,104</b>	<b>4,820,724</b>	<b>2,467,265</b>	<b>2,100,178</b>	<b>4,567,443</b>

	GROUP		
	31 December 2020		
	Consumer N'000	Pharma N'000	Total N'000
<b>Inventories - By Segment</b>			
Raw materials and consumables	1,138,667	-	1,138,667
Work in progress	299,739	-	299,739
Finished goods	1,216,849	575,405	1,792,254
Engineering spares	51,779	-	51,779
	<b>2,707,034</b>	<b>575,405</b>	<b>3,282,439</b>

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
<b>15 Trade and other receivables</b>						
Trade receivables	5,508,081	4,169,322	5,154,108	5,508,081	4,169,322	5,154,108
Receivables from related parties	9,389	233,163	31,909	9,389	233,163	31,909
Employee loans and advances	63,783	58,280	7,602	63,783	58,280	7,602
Other receivables	295,165	189,189	1,324,499	295,165	189,189	1,324,499
	<b>5,876,418</b>	<b>4,649,954</b>	<b>6,518,118</b>	<b>5,876,418</b>	<b>4,649,954</b>	<b>6,518,118</b>

15.1 Trade receivables

GROUP AND COMPANY			
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000
Trade receivables	5,614,176	4,280,195	5,262,828
Impairment loss	(106,095)	(110,873)	(108,720)
	<b>5,508,081</b>	<b>4,169,322</b>	<b>5,154,108</b>

Trade receivables are non-interest bearing and are generally on 60 day terms. The Group sells through distributors within Nigeria. The Group's policy states that a provision of 100% is made on all receivables over 360 days and other rates detailed in the tables below for invoices overdue for 181 to 360 days, 61 to 180 days and 0 to 60 days bracket. The provision matrix is arrived at after incorporating forward-looking information into historical customer default rates and, where appropriate, group receivables into customer segments that have similar loss patterns

Age of receivables that are past due but not impaired:

GROUP AND COMPANY			
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000
Movement in the allowance for doubtful debts			
Balance at 1 January	110,873	108,952	108,952
Additional provision	54,619	73,494	114,128
Recoveries	(59,398)	(71,573)	(114,360)
	<b>106,095</b>	<b>110,873</b>	<b>108,720</b>

15.2 Other receivables

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
Other receivables	295,165	189,189	1,324,499	295,165	189,189	1,324,499
	<b>295,165</b>	<b>189,189</b>	<b>1,324,499</b>	<b>295,165</b>	<b>189,189</b>	<b>1,324,499</b>

The fair values of trade and other receivables are the same as their carrying amounts.

16 Other assets

GROUP AND COMPANY			
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
Advance to Vendor	97,523	55,629	159,901
Advance to bank for bid	70,907	251,248	-
Prepaid rent	77,615	46,550	80,786
Prepaid insurance	13,106	8,898	23,583
Other prepayments	23,732	11,450	21,637
	<b>282,883</b>	<b>373,775</b>	<b>285,907</b>
Current	282,883	373,775	285,907
Non Current	-	-	-
	<b>282,883</b>	<b>373,775</b>	<b>285,907</b>

17 Cash and cash equivalents

For the purposes of the consolidated and separate statement of cash flows, cash and cash equivalents include cash and bank balances, net of outstanding bank overdrafts. Cash and cash equivalents at the end of the period as shown in the consolidated and separate statement of cash flows can be reconciled to related items in the consolidated and separate statements of financial position as follows:

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
<b>Cash at bank:</b>						
Current account balances	8,389,605	11,161,771	7,024,230	8,389,605	11,161,771	7,024,230
Restricted Cash	1,747,110	1,734,971	1,674,902	1,747,110	1,734,971	1,674,902
	<b>10,136,715</b>	<b>12,896,742</b>	<b>8,699,132</b>	<b>10,136,715</b>	<b>12,896,742</b>	<b>8,699,132</b>
Bank overdraft	-	(11,160)	-	-	(11,160)	-
Cash and cash equivalents	<b>10,136,715</b>	<b>12,885,582</b>	<b>8,699,132</b>	<b>10,136,715</b>	<b>12,885,582</b>	<b>8,699,132</b>

18 Issued capital and share premium

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	Thousands	Thousands	Thousands	Thousands	Thousands	Thousands
<b>Authorised shares</b>						
Ordinary shares of 50k each	1,500,000	1,500,000	1,500,000	1,500,000	1,500,000	1,500,000
	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>	<b>N'000</b>
Ordinary shares of 50k each	750,000	750,000	750,000	750,000	750,000	750,000

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

	Thousands	Thousands	Thousands	Thousands	Thousands	Thousands
<b>18.1 Ordinary shares issued and fully paid</b>	1,195,876	1,195,876	1,195,876	1,195,876	1,195,876	1,195,876
Ordinary shares of 50k each						
	N'000	N'000	N'000	N'000	N'000	N'000
Ordinary shares of 50k each	597,939	597,939	597,939	597,939	597,939	597,939
	N'000	N'000	N'000	N'000	N'000	N'000
<b>18.2 Share premium</b>	51,395	51,395	51,395	51,395	51,395	51,395

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
<b>19 Trade and other payables</b>	N'000	N'000	N'000	N'000	N'000	N'000
Trade payables	548,551	746,702	552,725	548,551	746,702	552,725
Amounts due to related parties (Note 22)	10,301,308	9,332,079	8,217,016	10,488,221	9,521,727	8,407,664
Unclaimed dividends	1,226,654	1,280,929	1,229,074	1,226,654	1,280,929	1,229,074
Dividend payable	804,868	582,836	582,836	804,868	582,836	582,836
Pension payables	9,880	-	5,644	9,879	-	5,644
Other payables	411,070	528,878	499,899	411,070	528,878	499,899
Accruals	1,222,780	1,108,219	1,938,552	1,219,746	1,104,335	1,935,299
	<b>14,525,111</b>	<b>13,579,643</b>	<b>13,025,746</b>	<b>14,708,989</b>	<b>13,765,407</b>	<b>13,213,141</b>

Terms and conditions of the above financial and non-financial liabilities:

- Trade payables are non-interest bearing and are normally settled on 60-day terms.
- Other payables and accruals are non-interest bearing and have an average term of six months.
- Terms and conditions relating to related party receivables are disclosed in Note 21

The fair values of trade and other payables are equal to their carrying amounts as the impact of discounting is not considered to be significant.

**20 Contract Liabilities**

	GROUP AND COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000
Advance from customers	97,417	9,844	5,820
Trade incentives	37,466	95,762	55,954
	<b>59,951</b>	<b>105,606</b>	<b>61,774</b>

**22 Related party disclosures**

The financial statements include the financial statements of the Company and those of Winster Pharmaceutical Limited, a wholly owned subsidiary which was incorporated in Nigeria. The Group share of the equity of Winster Pharmaceutical Limited remains at 100% throughout all reporting periods shown. There are no restrictions on the ability of the subsidiary to use assets of the Group, or settle its obligations.

The following table provides the total amount of transactions that have been entered into with related parties; as well as the outstanding balances for the transactions as at 30 September 2021, 31 December 2020 and 30 September 2020.

	GROUP									
	Purchases from related parties		Amounts owed by related parties				Amounts owed to related parties			
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021
	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000
<b>Subsidiary:</b>										
Winster Pharmaceuticals Limited:	-	-	-	-	-	-	-	-	-	190,648
<b>Other sister companies:</b>										
GSK Pharmaceutical Nigeria Limited	-	1,854,181	-	-	-	-	1,682,126	998,866	316,568	-
GSK Biological Manufacturing Limited	18,758	53,973	29,744	-	-	-	27,471	55,942	30,172	-
GSK Consumer Healthcare S.A. Pty Ltd	-	-	-	9,389	-	30,333	-	-	-	-
GlaxoSmithKline Export Limited UK	6,573,202	4,389,711	3,848,557	-	-	-	3,279,719	4,830,881	4,844,875	-
GlaxoSmithKline Consumer Trading Services (JDE)	1,771,211	1,106,468	2,827,301	-	198,850	-	1,948,770	432,852	317,140	-
GlaxoSmithKline Limited, Kenya	-	-	-	1,716	1,576	-	-	-	-	-
GlaxoSmithKline South Africa (Pty) Limited	-	-	-	-	-	-	75,954	29,747	3,340	-
GlaxoSmithKline Consumer Trading Services CERPS ASGN	-	-	496,951	-	-	-	-	-	-	2,887,746
GSK OPS UK Area	-	-	-	-	-	-	-	-	-	-
GSK Trading Service	3,955,786	2,828,746	-	-	-	-	3,181,956	2,975,274	-	-
GlaxoSmithKline Consumer Healthcare UK TA	-	-	-	-	-	-	4,135	-	-	-
GlaxoSmithKline Consumer Healthcare Pte. Ltd.	-	-	-	32,597	-	-	-	-	-	-
Glaxosmithkline Services Unlimited	-	-	-	-	-	-	101,176	8,517	7,823	-
<b>Total</b>	<b>12,318,957</b>	<b>10,233,079</b>	<b>7,202,553</b>	<b>9,389</b>	<b>233,163</b>	<b>31,909</b>	<b>10,301,308</b>	<b>9,332,079</b>	<b>8,217,016</b>	

GlaxoSmithKline Consumer Nigeria Plc  
Notes to the unaudited consolidated and separate financial statements (continued)  
For the period ended 30 September 2021

	COMPANY								
	Purchases from related parties			Amounts owed by related parties			Amounts owed to related parties		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000	N'000
<b>Subsidiary:</b>									
Winster Pharmaceuticals Limited:	-	-	-	-	-	-	186,913	189,648	-
<b>Other sister companies:</b>									
GSK Pharmaceutical Nigeria Limited	-	1,854,181	-	-	-	-	1,682,126	998,866	316,568
GSK Biological Manufacturing Limited	18,758	53,973	29,744	-	-	-	27,471	55,942	30,172
GSK Consumer Healthcare S.A. Pty Ltd	-	-	-	9,389	-	30,333	-	-	-
GlaxoSmithKline Export Limited UK	6,573,202	4,389,711	3,848,557	-	-	-	3,279,719	4,830,881	4,844,875
GlaxoSmithKline Consumer Trading Services (JDE)	1,771,211	1,106,468	2,827,301	-	198,850	-	1,948,770	432,852	317,140
GlaxoSmithKline Limited, Kenya	-	-	-	-	1,716	1,576	-	-	-
GlaxoSmithKline South Africa (Pty) Limited	-	-	-	-	-	-	75,954	29,747	3,340
GlaxoSmithKline Consumer Trading Services CERPS ASGN	-	-	496,951	-	-	-	-	-	2,887,746
GSK OPS UK Area	-	-	-	-	-	-	-	-	-
GSK Trading Service	3,955,786	2,828,746	-	-	-	-	3,181,956	2,975,274	-
GlaxoSmithKline Consumer Healthcare UK TA	-	-	-	-	-	-	4,135	-	-
GlaxoSmithKline Consumer Healthcare Pte. Ltd.	-	-	-	-	32,597	-	-	-	-
Glaxosmithkline Services Unlimited	-	-	-	-	-	-	101,176	8,517	7,823
<b>Total</b>	<b>12,318,957</b>	<b>10,233,079</b>	<b>7,202,553</b>	<b>9,389</b>	<b>233,163</b>	<b>31,909</b>	<b>10,488,221</b>	<b>9,521,727</b>	<b>8,407,664</b>

Transactions and balances receivable and payable at the year are further analysed as follows:

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
<b>Receivable from related parties:</b>						
Local	-	-	-	-	-	-
Foreign	9,389	233,163	31,909	9,389	233,163	31,909
	<b>9,389</b>	<b>233,163</b>	<b>31,909</b>	<b>9,389</b>	<b>233,163</b>	<b>31,909</b>
<b>Payable to related parties:</b>						
Local	1,682,126	998,866	316,568	1,682,126	1,188,514	316,568
Foreign	8,619,182	8,333,213	7,900,448	8,806,095	8,333,213	8,091,096
	<b>10,301,308</b>	<b>9,332,079</b>	<b>8,217,016</b>	<b>10,488,221</b>	<b>9,521,727</b>	<b>8,407,664</b>

There were sales of goods amounting to NGN148million to related parties for the period ended 30 September 2021 (2020:nil).

**The ultimate parent company**

The ultimate parent company of the Group is GlaxoSmithKline Plc, United Kingdom.

**Terms and conditions of transactions with related parties**

Purchases from related parties are for inventory items as well as IT support services provided.

Outstanding balances at the period end are unsecured and interest free. There have been no guarantees provided or received for any related party receivables or payables. For the period ended 30 September 2021, the Group has not recorded any impairment of receivables relating to amounts owed by related parties (2020: Nil). This assessment is undertaken each financial year by examining the financial position of the related party and the market in which the related party operates.

**23 Financial risk management objectives and policies**

The Group is exposed to market risk, credit risk and liquidity risk.

The Group's senior management oversees the management of these risks. The Group's senior management is supported by a Finance Committee that advises on financial risks and the appropriate financial risk governance framework for the Group. The Finance committee provides assurance to the Group's senior management that the Group's financial risk-taking activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with Group policies and risk appetite.

The Board of Directors reviews and agrees policies for managing each of these risks which are summarised below.

**Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise four types of risk: interest rate risk, currency risk, commodity price risk and other price risk. Financial instruments affected by market risk are mainly the Group's loans and receivables and short-term deposits.



**GlaxoSmithKline Consumer Nigeria Plc**  
**Notes to the unaudited consolidated and separate financial statements (continued)**  
**For the period ended 30 September 2021**

(i) **Interest rate risk**

The Group places surplus funds with its Group Corporate bankers on short term basis. The transaction is strictly between the bank and the Group at a fixed interest rate paid upfront and not affected by fluctuations in rates during the tenor. Each fixed deposit is covered by a certificate of deposit issued by the bank.

(ii) **Foreign currency risk**

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (i.e. when revenue/expense and asset/liabilities are denominated in a different currency from the Group's functional currency), the Group's exposure for the reporting periods shown is mainly due to related party receivables and payables denominated in foreign currencies.

The Group manages its foreign currency risk by converting its transactions denominated in foreign currency to its functional currency on the date of receipt of invoice and records any exchange gain or loss on settlement of the invoice as they arise, without hedging. The Group invoices goods to its foreign third party in the functional currency - the Nigerian Naira (NGN). The Group's foreign currency risk is mainly as a result of exposure to the GBP and USD and arises predominantly as a result of amounts receivable and payable to related parties.

**Credit risk**

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily for trade receivables) and cash and short term deposit, including deposits with banks, amount due from related parties and staff loans. The Group manages employee loans by ensuring that each employee does not exceed a loan greater than one-third of his or her net pay, and only employees who meet this requirement receives a loan facility from the Company. Additionally, any employee granted a loan in excess of the above limit must have a staff benefit (defined benefit) as collateral. In respect of bank balances, the Group maintains balances in Agusto & Co rated banks.

**Liquidity risk**

The Group monitors its risk to shortage of funds using a recurring liquidity planning tool. The objective is to maintain a balance between working capital and medium term business expansion funding requirements. Access to sources of short and medium term funding is sufficiently available and the Group has secured adequate overdraft facilities with its bankers which have rarely been utilised.

**Capital management**

Capital includes equity attributable to the equity holders of the parent.

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and maximise shareholder value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders or issue new shares.

No changes were made in the objectives, policies or processes for managing capital during the period ended 30 September 2021.

The Group monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Group's policy is to keep the gearing ratio within a reasonable level. The Group includes within net debt, interest bearing loans and borrowings, trade and other payables, less cash and cash equivalents.

	GROUP			COMPANY		
	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020	Nine months ended 30 September, 2021	31 December 2020	Nine months ended 30 September, 2020
	N'000	N'000	N'000	N'000	N'000	N'000
Trade and other payables (Note 18)	14,605,202	13,803,019	13,087,520	14,789,080	13,988,783	13,274,915
Less: cash and bank balances (Note 16)	10,136,715	12,896,742	8,699,132	10,136,715	12,896,742	8,699,132
	<u>4,468,487</u>	<u>906,277</u>	<u>4,388,388</u>	<u>4,652,365</u>	<u>1,092,041</u>	<u>4,575,783</u>
Equity	8,763,338	9,118,990	8,931,080	8,593,366	8,947,132	8,757,863
Capital and net debt	<u>13,231,824</u>	<u>10,025,267</u>	<u>13,319,468</u>	<u>13,245,730</u>	<u>10,039,173</u>	<u>13,333,646</u>
<b>Gearing ratio (Cap to Zero)</b>	<b>34%</b>	<b>9%</b>	<b>33%</b>	<b>35%</b>	<b>11%</b>	<b>34%</b>

**24 Fair Value of Financial Instrument**

The Directors consider that the carrying amounts of financial assets and financial liabilities recorded in the financial statements approximate their fair values.

**25 Financial commitments**

The Company has no financial commitment for the period ended 30 September, 2021.